Leerink Partnrs Predicts Revvity’s Q4 Earnings (NYSE:RVTY)

Revvity Inc. (NYSE:RVTY) – Stock analysts at Leerink Partnrs reduced their Q4 2025 earnings per share (EPS) estimates for shares of Revvity in a report issued on Sunday, September 14th. Leerink Partnrs analyst P. Souda now forecasts that the company will earn $1.54 per share for the quarter, down from their prior forecast of $1.56. The consensus estimate for Revvity’s current full-year earnings is $4.94 per share. Leerink Partnrs also issued estimates for Revvity’s Q1 2026 earnings at $1.14 EPS and Q3 2026 earnings at $1.35 EPS.

Revvity (NYSE:RVTY) last issued its earnings results on Monday, July 28th. The company reported $1.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.04. Revvity had a return on equity of 7.66% and a net margin of 10.19%.The business had revenue of $720.28 million during the quarter, compared to analysts’ expectations of $711.26 million. During the same quarter in the prior year, the firm earned $1.22 EPS. The business’s revenue for the quarter was up 4.1% compared to the same quarter last year. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS.

A number of other equities analysts have also recently issued reports on RVTY. Evercore ISI lowered their target price on Revvity from $116.00 to $115.00 and set an “outperform” rating for the company in a report on Tuesday, July 8th. Wall Street Zen cut Revvity from a “buy” rating to a “hold” rating in a research note on Sunday, August 3rd. Raymond James Financial reissued an “outperform” rating and issued a $115.00 price target (down previously from $120.00) on shares of Revvity in a research note on Tuesday, July 29th. Bank of America decreased their price target on Revvity from $116.00 to $110.00 and set a “buy” rating for the company in a research note on Thursday, June 26th. Finally, Stifel Nicolaus decreased their price target on Revvity from $120.00 to $110.00 and set a “hold” rating for the company in a research note on Tuesday, July 29th. Ten equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $120.07.

Revvity Price Performance

Shares of RVTY opened at $85.40 on Wednesday. Revvity has a 12-month low of $81.36 and a 12-month high of $129.50. The business has a 50-day simple moving average of $90.62 and a two-hundred day simple moving average of $95.62. The company has a quick ratio of 2.75, a current ratio of 3.33 and a debt-to-equity ratio of 0.43. The stock has a market cap of $9.91 billion, a PE ratio of 36.18, a PEG ratio of 2.29 and a beta of 0.94.

Revvity Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 17th will be given a dividend of $0.07 per share. The ex-dividend date is Friday, October 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. Revvity’s dividend payout ratio is presently 11.86%.

Institutional Investors Weigh In On Revvity

Several institutional investors and hedge funds have recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. boosted its position in shares of Revvity by 8.5% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 22,515,711 shares of the company’s stock valued at $2,382,163,000 after purchasing an additional 1,754,403 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Revvity by 0.6% in the first quarter. Vanguard Group Inc. now owns 14,382,849 shares of the company’s stock worth $1,521,705,000 after acquiring an additional 92,638 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Revvity by 25.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 9,563,911 shares of the company’s stock worth $1,011,863,000 after acquiring an additional 1,932,314 shares in the last quarter. EdgePoint Investment Group Inc. boosted its holdings in Revvity by 26.7% in the second quarter. EdgePoint Investment Group Inc. now owns 6,789,660 shares of the company’s stock worth $656,696,000 after acquiring an additional 1,428,813 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Revvity by 1.8% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,444,645 shares of the company’s stock worth $364,443,000 after acquiring an additional 62,307 shares in the last quarter. Institutional investors own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.